October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial ...
The 2025 Autumn Fair in Hanoi has attracted large crowds over one week, with the cinema zone emerging as a major cultural ...
Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...
BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback